Biotechnology · Radnor, Pennsylvania, United States
$29.28
-3.38% (-$1.03)2026-07-09
Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$5.1M, 32 sales vs 16 buys)
Net Income-$39.3M
EPS$-0.47
Market Cap$2.4B
Price Performance
Historical data including institutional events
Company Profile
J
Jon Congleton
CEO & Executive Director
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
